mhra
MHRA sets out 2026–2027 clinical investigation fee waivers
MHRA’s programme provides ten application fee waivers for eligible UK micro and small enterprises planning clinical investigations of innovative medical devices.

What Changed
The Medicines and Healthcare products Regulatory Agency (MHRA) has extended its medical device clinical investigation application fee-waiver programme into 2026–2027. Ten waivers are available to eligible micro and small enterprises, removing the usual clinical investigation application fee entirely for successful applicants.
The programme covers Class I, IIa and IIb devices and now also includes Class III devices. Active implantable devices remain excluded, and only one waiver can be approved per applicant.
Who Is Affected
The programme targets UK-based businesses that have obtained micro or small enterprise status from MHRA before applying for a waiver.
To qualify as innovative, a device must be new or a novel modification of existing technologies. There must be no solution meeting the same clinical need that has UK regulatory approval. The device must also be scalable, with the ultimate aim of benefiting the health and social care system, patients or care providers.
Regulatory and Technical Implications
The waiver removes the device application fee, not application validation or regulatory assessment. For studies that also involve a clinical trial of an investigational medicinal product, it applies only to the device component. The full medicinal-product trial review fee remains payable.
MHRA’s guidance requires notification at least 60 days before an investigation starts where notification is required. For Great Britain, the 60-day assessment clock begins the day after acceptance of a valid application. Devices already UKCA, CE or CE UKNI marked for the purpose being investigated do not require notification.
Manufacturer Actions
Businesses should first obtain MHRA confirmation of their enterprise status, then check innovative-device eligibility with the agency. Applicants must send CI-applications@mhra.gov.uk a cover letter describing the device, explaining how it meets all three innovation criteria and outlining the planned investigation, alongside their enterprise-status confirmation.
MHRA states that its team will review this information within five working days of receipt and confirm eligibility and waiver availability. After eligibility confirmation, applicants should submit through IRAS as soon as possible. A waiver is granted following successful validation; applicants whose submissions are invalid have an opportunity to resubmit.
Confirmed Dates
The programme runs from 20 April 2026 until 5 April 2027, or ends earlier if all ten waivers have been granted.
The MHRA guidance page was first published on 18 December 2014 and lists 6 November 2026 as its last update. That page-update date is distinct from the programme’s start date.
Official Source
MHRA’s GOV.UK guidance, “Clinical investigations for medical devices”, sets out the programme conditions and clinical investigation application procedures.
Https://www.gov.uk/guidance/notify-mhra-about-a-clinical-investigation-for-a-medical-device
Source and related services
Clinical investigations for medical devices ↗Source date: 06/11/2026
This news provides general information and does not replace device-specific legal or conformity assessment advice.